부산대학교 도서관

The onset of type 2 diabetes increases the risk of vascular complications and death. We know now that that this risk begins long before the diabetes diagnosis. Prediabetes and type 2 diabetes are not separate entities in practice and exist within a continuum of dysglycaemia and vascular risk that increases in severity over time. This excess risk requires early intervention with lifestyle therapy supported with pharmacologic antidiabetic therapy, intensified promptly where necessary throughout the duration of the diabetes continuum. Metformin is an evidence-based treatment for preventing prediabetes and improves cardiovascular outcomes in people with type 2 diabetes from diagnosis onwards. Newer agents (SGLT2 inhibitors and GLP-1 agonists) are appropriate for people presenting with type 2 diabetes and significant cardiovascular comorbidity. Additional therapies should be used without delay to achieve patients' individualised HbAlc goals and to minimise cardiovascular risk. Keywords: prediabetes, type 2 diabetes, diabetes complications, antidiabetic therapy
Introduction The publication of the Diabetes Control and Complications Trial in 1993 proved conclusively that long-term hyperglycaemia in the setting of type 1 diabetes was associated with cardiorenal complications with [...]